The stock of BTG plc (LON:BTG) is a huge mover today! The stock increased 3.56% or GBX 22.48 on November 3, hitting GBX 653.98. About 944,455 shares traded hands or 69.27% up from the average. BTG plc (LON:BTG) has risen 4.08% since April 6, 2016 and is uptrending. It has outperformed by 2.87% the S&P500.
The move comes after 7 months positive chart setup for the GBX 2.52 billion company. It was reported on Nov, 3 by Barchart.com. We have GBX 1065.99 PT which if reached, will make LON:BTG worth GBX 1.59 billion more.
BTG plc (LON:BTG) Ratings Coverage
Out of 9 analysts covering BTG PLC (LON:BTG), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. BTG PLC has been the topic of 70 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, June 27 by Deutsche Bank. The stock of BTG plc (LON:BTG) earned “Neutral” rating by JP Morgan on Wednesday, May 18. The company was maintained on Thursday, August 6 by FinnCap. As per Friday, June 24, the company rating was maintained by Deutsche Bank. The stock of BTG plc (LON:BTG) has “Neutral” rating given on Tuesday, August 16 by JP Morgan. The firm has “Hold” rating given on Tuesday, November 10 by Stifel Nicolaus. The stock has “Sell” rating given by Stifel Nicolaus on Thursday, August 6. The stock of BTG plc (LON:BTG) earned “Sell” rating by Stifel Nicolaus on Tuesday, October 6. Deutsche Bank maintained BTG plc (LON:BTG) on Tuesday, July 12 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Friday, July 15.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The company has a market cap of 2.52 billion GBP. The Firm operates through three divisions: Interventional Medicine, Specialty Pharmaceuticals and Licensing. It has a 41.96 P/E ratio. The Interventional Medicine segment includes oncology, vascular and pulmonology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.